YGYFKN-1

YGYFKN-1 is an investigational small molecule anticoagulant developed by Silver Valley Pharmaceutical (Beijing Yingu Pharmaceutical). Currently in the preclinical stage of development, it is being studied for the treatment of various blood coagulation disorders. The drug is designed to target the coagulation cascade, specifically inhibiting Coagulation factor XIa (FXIa), which plays a key role in the intrinsic pathway of blood clotting. By targeting FXIa, YGYFKN-1 aims to provide a therapeutic effect with a reduced risk of bleeding complications compared to traditional anticoagulants like warfarin or direct thrombin inhibitors. As a small molecule, it is likely intended for oral administration to manage or prevent thrombotic events.